One of the sort of miracle drugs right now that everyone's talking about are GLP-1s and how they have so many applications. Obviously, they're very expensive. The last administration had talked about opening them up to people.Obviously, it's a big upfront cost, but ultimately because it makes people healthier down the line, it might pay off. What are your thoughts on making GLP1s available for weight loss in Medicare. Can we afford it or can we afford not to do it.>> Uh, it's the only question I'm going to ...

this is propaganda btwmounjaro 100% works (it's the 2nd version of ozempic, way better)it's *insane* how well it worksI lost 50-60 lbs in 1 year by basically changing nothing elseit also helps you quit nicotine (i quit with 0 relapse)it should be in the public waterAutism Capital 🧩 (@AutismCapital):🚨 TRUMP: “I call Ozempic the fat drug. Sometimes it works for people, but the ones I’ve seen it hasn’t worked that well. I have friends that are fat and they said ‘I lost some weight,’ I said ‘You don’t look it t ...

Core Insights - An experimental GLP-1 pill named orforglipron has shown significant weight loss results in clinical trials without requiring weekly injections [1] Group 1 - The clinical trial results indicate that orforglipron promotes substantial weight loss [1]

Product & Technology - Signos leverages AI and continuous glucose monitoring (CGM) via a wearable biosensor to provide real-time metabolic insights for weight management [2][3] - The device, featuring a micro-needle, is worn for 15 days and provides data accessible via a phone app [3][4] - Signos aims to predict weight-related outcomes by providing personalized recommendations (e.g, suggesting a walk after a meal) based on glucose levels [5] - Signos integrates with other wearable devices like Apple Watch, complementing their data with AI-driven predictions [13][14] Market & Competition - Signos positions itself as a complementary solution to GLP-1 drugs, targeting a broader audience beyond those with obesity, focusing on weight loss and maintenance [7] - The company aims to establish metabolism as the "fifth vital sign," promoting continuous monitoring outside of clinical settings [8] - The FDA clearance covers the device's accuracy in measuring glucose levels for weight management, including weight loss and maintenance [9] Business Model & Financials - The service costs $129 per month and is FSA/HSA eligible [6] - Signos is actively pursuing partnerships with insurers for reimbursement coverage [6] Clinical Benefits - Stabilizing glucose levels can lead to improved sleep quality, as demonstrated by a user experience of tripled deep sleep duration [11][12]

Or maybe he’s in his 50s and he was advised he can’t take heroic doses of steroids anymore if he wants to live a long life.Gabe Pluguez | Default Kings (@Gabepluguez):Everyone's shocked about The Rock's massive weight loss…But he recently sat down with Dr. Mark Hyman & broke down what's REALLY going on with his health.What he revealed will make you rethink going to the doctor…Here are my top 8 takeaways: https://t.co/yNlg5VGdDK ...

Switching gears, Eli Lily surging almost 6%. It led the S&P 500 today. Their obesity pill cleared yet another late stage trial.Patients with type 2 diabetes and obesity losing an average 10 a.5% of their body weight after 72 weeks is on the highest dose. For more on what may come next, city research managing director Jeff Meechum joining us now. Jeff, great to have you on the show.What did these results mean for Lily. >> Awesome. Thanks for having me, Brian.Um, yes. So, the results here are derisking from t ...

Eli Lily shares. Let's have a look at those after that news that we just uh reported that the pharma giant released more data on its obesity pill. Patients with obesity and diabetes lost about 10.5% of their body weight.The data clears the way for Lily to seek regulatory approval. Shares are up 1.7% when they got some data on this a month or so ago or just under a month ago they did fall. Let's get clarity on which bit of the data outweighs the other.Tim Anderson, Bank of America Security senior pharma anal ...

Weight Management & GLP-1s - Serena Williams partners with Ro to use GLP-1s for weight management [2] - She has been trying to lose weight since her first child in 2017, despite consistent workouts and healthy eating [2][3][9] - Traditional methods like various diets and exercise routines were ineffective for her [4][5][6] - GLP-1s helped her achieve results while maintaining her existing healthy habits [10] - She emphasizes the health aspect and feeling lighter and more confident [18] - Ro provides easy access to medicine, doctor consultations, and insurance checks [15] - She hopes to reduce the stigma around weight loss medication and make it more accessible [17] Public Image & Haters - She addresses potential criticism for using GLP-1s, stating she doesn't care about haters [12][13] - She has faced criticism throughout her career and is good at blocking out noise [13][14] - She emphasizes the importance of sharing her story and journey [15] New Podcast: Stockton Street - Serena and Venus Williams are starting a podcast called Stockton Street, named after their childhood street in Compton [20] - The podcast will cover pop culture, sports, lifestyle, fashion, and design [23] - They aim to share open conversations and insights into their lives [23] Career & Resilience - She attributes her success to hard work and dedication [27] - She acknowledges the importance of resilience in tennis and life [29][30]

Health & Wellness Industry Trends - GLP-1s are gaining popularity as a weight loss solution [2] - Individuals are seeking medical interventions like GLP-1s after struggling with weight loss through traditional methods such as diet and exercise [1][2][3] - Personal experiences and testimonials are influencing decisions to try GLP-1s [2] GLP-1s & Weight Management - GLP-1s are perceived as a tool to achieve weight loss goals when other methods have failed [1][3] - GLP-1s can provide noticeable results, such as fitting into previously unwearable clothing [3] Public Perception & Personal Choice - Individuals may face criticism or judgment for using GLP-1s [3] - Personal health decisions should not be dictated by others' opinions [4]

Market Dynamics & Competition - Novo Nordisk's oral wegovy shows promising 16.6% weight loss with good tolerability, potentially shifting the oral market split [3][4] - The oral wegovy faces a "food effect" issue, requiring specific consumption conditions (fasting, water, waiting 30 minutes), potentially limiting its use to maintenance after initial weight loss with injectables [4][7] - Manufacturing costs for oral wegovy are higher due to the larger peptide dosage (25mg) compared to the weekly injectable (2.4mg) [7] - The weight loss drug space is experiencing pricing headwinds and some pricing concessions, potentially influenced by the CVS exclusive deal [8][9] Company Performance & Expectations - Lilly's stock experienced a significant drop (down 14%) due to data expectations being set too high (above 15% efficacy), raising questions about the long-term strength of their franchise [1][2] - There was a disconnect between Novo Nordisk's positive presentation of their data (27 pounds average weight loss) and the market's expectations [9] - Companies need to learn from competitors' successes and failures in managing expectations and messaging around drug data [13]